139 related articles for article (PubMed ID: 28623364)
1. Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats.
Bergmann R; Kubeil M; Zarschler K; Chhabra S; Tajhya RB; Beeton C; Pennington MW; Bachmann M; Norton RS; Stephan H
Sci Rep; 2017 Jun; 7(1):3756. PubMed ID: 28623364
[TBL] [Abstract][Full Text] [Related]
2. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases.
Jin L; Zhou QT; Chan HK; Larson IC; Pennington MW; Morales RAV; Boyd BJ; Norton RS; Nicolazzo JA
J Pharm Sci; 2016 Feb; 105(2):650-656. PubMed ID: 26869426
[TBL] [Abstract][Full Text] [Related]
4. Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa.
Jin L; Boyd BJ; Larson IC; Pennington MW; Norton RS; Nicolazzo JA
J Pharm Sci; 2016 Jul; 105(7):2173-9. PubMed ID: 27312508
[TBL] [Abstract][Full Text] [Related]
5. A Biodistribution Study of the Radiolabeled Kv1.3-Blocking Peptide DOTA-HsTX1[R14A] Demonstrates Brain Uptake in a Mouse Model of Neuroinflammation.
Reddiar SB; de Veer M; Paterson BM; Sepehrizadeh T; Wai DCC; Csoti A; Panyi G; Nicolazzo JA; Norton RS
Mol Pharm; 2023 Jan; 20(1):255-266. PubMed ID: 36331024
[TBL] [Abstract][Full Text] [Related]
6. A Fluorescent Peptide Toxin for Selective Visualization of the Voltage-Gated Potassium Channel K
Wai DCC; Naseem MU; Mocsár G; Babu Reddiar S; Pan Y; Csoti A; Hajdu P; Nowell C; Nicolazzo JA; Panyi G; Norton RS
Bioconjug Chem; 2022 Nov; 33(11):2197-2212. PubMed ID: 36330854
[TBL] [Abstract][Full Text] [Related]
7. Lipopolysaccharide influences the plasma and brain pharmacokinetics of subcutaneously-administered HsTX1[R14A], a K
Reddiar SB; Jin L; Wai DCC; Csoti A; Panyi G; Norton RS; Nicolazzo JA
Toxicon; 2021 May; 195():29-36. PubMed ID: 33689790
[TBL] [Abstract][Full Text] [Related]
8. Blockade of Microglial Kv1.3 Potassium Channels by the Peptide HsTX1[R14A] Attenuates Lipopolysaccharide-mediated Neuroinflammation.
Nicolazzo JA; Pan Y; Di Stefano I; Choy KHC; Reddiar SB; Low YL; Wai DCC; Norton RS; Jin L
J Pharm Sci; 2022 Mar; 111(3):638-647. PubMed ID: 34767826
[TBL] [Abstract][Full Text] [Related]
9. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases.
Rashid MH; Huq R; Tanner MR; Chhabra S; Khoo KK; Estrada R; Dhawan V; Chauhan S; Pennington MW; Beeton C; Kuyucak S; Norton RS
Sci Rep; 2014 Mar; 4():4509. PubMed ID: 24676092
[TBL] [Abstract][Full Text] [Related]
10. Peripheral Administration of the Kv1.3-Blocking Peptide HsTX1[R14A] Improves Cognitive Performance in Senescence Accelerated SAMP8 Mice.
Pan Y; Kagawa Y; Sun J; Lucas DSD; Takechi R; Mamo JCL; Wai DCC; Norton RS; Jin L; Nicolazzo JA
Neurotherapeutics; 2023 Jul; 20(4):1198-1214. PubMed ID: 37226029
[TBL] [Abstract][Full Text] [Related]
11. Prolonged Plasma Exposure of the Kv1.3-Inhibitory Peptide HsTX1[R14A] by Subcutaneous Administration of a Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere Formulation.
Jin L; Pan Y; Pham AC; Boyd BJ; Norton RS; Nicolazzo JA
J Pharm Sci; 2021 Mar; 110(3):1182-1188. PubMed ID: 33065128
[TBL] [Abstract][Full Text] [Related]
12. The Kv1.3 K
Varga Z; Tajti G; Panyi G
Biol Futur; 2021 Mar; 72(1):75-83. PubMed ID: 34554500
[TBL] [Abstract][Full Text] [Related]
13. Free energy simulations of binding of HsTx1 toxin to Kv1 potassium channels: the basis of Kv1.3/Kv1.1 selectivity.
Rashid MH; Kuyucak S
J Phys Chem B; 2014 Jan; 118(3):707-16. PubMed ID: 24397610
[TBL] [Abstract][Full Text] [Related]
14. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
[TBL] [Abstract][Full Text] [Related]
15. The Kv1.3 channel blocker Vm24 enhances muscle glucose transporter 4 mobilization but does not reduce body-weight gain in diet-induced obese male rats.
Jaimes-Hoy L; Gurrola GB; Cisneros M; Joseph-Bravo P; Possani LD; Charli JL
Life Sci; 2017 Jul; 181():23-30. PubMed ID: 28549558
[TBL] [Abstract][Full Text] [Related]
16. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation.
Rashid MH; Heinzelmann G; Huq R; Tajhya RB; Chang SC; Chhabra S; Pennington MW; Beeton C; Norton RS; Kuyucak S
PLoS One; 2013; 8(11):e78712. PubMed ID: 24244345
[TBL] [Abstract][Full Text] [Related]
17. Peptide blockers of K
Chandy KG; Norton RS
Curr Opin Chem Biol; 2017 Jun; 38():97-107. PubMed ID: 28412597
[TBL] [Abstract][Full Text] [Related]
18. The voltage-gated potassium channel K
Tajti G; Wai DCC; Panyi G; Norton RS
Biochem Pharmacol; 2020 Nov; 181():114146. PubMed ID: 32653588
[TBL] [Abstract][Full Text] [Related]
19. Structural and functional consequences of the presence of a fourth disulfide bridge in the scorpion short toxins: solution structure of the potassium channel inhibitor HsTX1.
Savarin P; Romi-Lebrun R; Zinn-Justin S; Lebrun B; Nakajima T; Gilquin B; Menez A
Protein Sci; 1999 Dec; 8(12):2672-85. PubMed ID: 10631983
[TBL] [Abstract][Full Text] [Related]
20. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
